Cargando…
The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review
BACKGROUND: Glucocorticoid is one of the common and important strategies for the treatment of chimeric antigen receptor T (CAR-T) cell therapy-related toxicity. However, there has been a theoretical concern about whether glucocorticoids use can impact the expansion of CAR-T cells and thus impair its...
Autores principales: | Sun, Zhen, Xun, RenDe, Liu, MengSi, Wu, XiaoQin, Qu, HongTao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093636/ https://www.ncbi.nlm.nih.gov/pubmed/33959128 http://dx.doi.org/10.3389/fimmu.2021.646450 |
Ejemplares similares
-
Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review
por: Wu, XiaoQin, et al.
Publicado: (2021) -
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021) -
Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021) -
Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021) -
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
por: Riedell, Peter A., et al.
Publicado: (2020)